The web site logo

Joint Statement by EAS, IAS, and the NLA on CETP Inhibition and HDL

On May 6, the decision was made to halt a late-stage trial of dalcetrapib, an experimental cholesterol drug intended to boost high density lipoprotein-cholesterol (HDL-C). A late-stage study, the dal-OUTCOMES Phase III trial, showed that dalcetrapib was not working effectively. The below statement provides the joint response from the European Atherosclerosis Society, International Atherosclerosis Society and the National Lipid Association.

Read the Joint Statement by EAS, IAS and NLA

Back to Top

Dalcetrapib: Major Study Stopped

A late-stage trial of dalcetrapib, an experimental cholesterol drug, was halted on May 7, according to a statement issued by its manufacturer, Roche. The drug is intended to boost high density lipoprotein-cholesterol (HDL-C), but a late-stage study, the dal-OUTCOMES Phase III trial, showed that it was not working effectively.

Read statement from Roche

Read dalcetrapib article on Bloomberg

Back to Top

NLA Honors and Recognition

Congratulations to William Boden, MD, recipient of the Lifetime Membership Award, Avedis Khachadurian, MD, FNLA, recipient of the Distinguished Achievement Award, and Anne Goldberg, MD, FNLA, and Ralph La Forge, MSc, FNLA, recipients of the President's Service Award. These four honorees will be recognized at the Honors and Awards Ceremony on Saturday, June 2, during the Annual Scientific Sessions in Scottsdale, Arizona.

See past NLA award winners

Back to Top

NLA-Endorsed Grand Rounds on Reducing Residual Risk and Managing Complex Dyslipidemia

Select medical institutions are eligible to host an exciting new CME-certified in-hospital grand rounds program endorsed by the NLA. This new program examines the importance of lipoprotein management for secondary prevention of major adverse cardiac events in post-ACS patients. Participants will learn to recognize residual risk associated with statin therapy to lower LDL, as well as the limitations of current therapies to increase HDL. Participants also will increase awareness of novel therapies to increase HDL and reduce CVD. For more information, e-mail Rachon Cottman.

Back to Top

Integrated Approaches to Cardiometabolic Care

Register now for the ground-breaking, free CME program, Integrated Approaches to Cardiometabolic Care, which will be held June 15,2012 in Anaheim, CA. Designed for endorcrinologists, cardiologists and primary care physicians, this free, interactive CME program features expert clinical faculty examining the critical interrelationships between cardiometabolic risk and disease and provides evidence-based approaches for managing patients with complex cardiometabolic conditions.

Learn More

Back to Top

Cardiovascular Disease Prevention for Women: First Annual ASPC Southeastern Conference

Make plans to attend the inaugural American Society for Preventive Cardiology (ASPC) conference in Boca Raton, Florida, on April 28. The event will be co-chaired by Seth Baum, MD, and Stephen Kopecky, MD, and will feature several NLA members as program faculty. Earn up to seven CME/CE credits at this meeting, which has been endorsed by the NLA, the Preventive Cardiovascular Nurses Association, American Society of Hypertension, and the Florida Obstetric and Gynecologic Society.

Click here for more information

Back to Top

NLA Lipid Academy Now Available Online

Lipid Academy Online is a user-friendly, tech-savvy adaptation of the NLA's live training course. This series of 7 interactive modules provides a comprehensive indoctrination to lipid science and essential information for the systematic management of dyslipidemia and the metabolic syndrome. The one-of-a-kind course covers the core competencies in Lipidology, while preparing you to work more effectively in clinical practice.

Learn More

Back to Top

Learn from Leading Experts in a City Near You- Join in a Lipid Forum.

This exciting, case-based, audience-driven, interactive CME Meeting Series will feature world-renowned specialists in lipidology discussing HDL functionality and quantification, residual cardiovascular risk, the latest clinical trials as well as emerging therapies for HDL modulation, CETP inhibition and reverse cholesterol transport. This activity will be highlighted by “Meet the Experts” breakout sessions that will allow the learner to discuss therapeutic dilemmas, complex topics, and challenging cases in greater detail with all the faculty.

Register Today

Back to Top

Don't Wait! Abstracts Due Today by 5 p.m. PDT

Submit your research for presentation as a poster during the 2012 NLA Scientific Sessions! The deadline for abstract submissions is Monday, April 2 at 5 p.m. PDT. All accepted abstracts will be published in the Journal of Clinical Lipidology.

NLA Young Investigator Award
Lead presenters with accepted abstracts who are Young Investigators (in-training students, residents and fellows or members in practice for <5 years) will receive free registration to the 2012 NLA Scientific Sessions. Their submissions also will be eligible for the NLA Young Investigator Award* with cash awards of $1,000 to first place and $500 to second and third place. The first place winner also will be selected to give an oral presentation during the sessions. *Sponsored by LipoScience, Inc.

View Categories and Submission Guidelines

Back to Top

Celebrate the NLA’s 10th Anniversary at the 2012 Annual Scientific Sessions

This year’s theme is Extending the Reach and Inclusiveness of Lipidology. This 4-day comprehensive learning experience will feature a wide variety of scientific sessions, symposia, case presentations, poster presentations, and oral presentations of selected abstracts that provide practical applications for applying the latest research in your clinical practice. In addition, the NLA will be hosting a gala 10th Anniversary Special Event featuring dinner and dancing to honor the past presidents of the NLA and support the Foundation of the NLA.

Program Highlights include:

• A Masters Summit on Emerging LDL Therapies
• Keynote Presentation from Dr. William E. Boden:  Discussion of AIM-HIGH and COURAGE Trials
• A Debate Session entitled, Is it EPA or EPA and DHA? Only Your Neighborhood Lipidologist Knows for Sure,
• Atherosclerotic Plaque: Imaging and Dynamics
• Special Public Interest Lunch – “Why We Get Fat in the U.S.” with Science Writer Gary Taubes
• Sugar, Salt and Everything that Peppers the Landscape

Learn More

Back to Top

NLA Cosponsors FH and Genetic Dyslipidemia Meeting

In conjunction with the Australian Atherosclerosis Society and the International FH Foundation, the NLA is cosponsoring an FH and Genetic Dyslipidemia Satellite Meeting in Manly Beach, Australia, from March 23-25, 2012. The series will feature a world renowned faculty including several NLA representatives.

View FH and Genetic Dyslipidemia Satellite Meeting Program

Back to Top

2011 PQRS Submission Deadline Extended

The CECity PQRIwizard deadline for reporting has been extended to March 15, 2012. PQRIwizard helps guide users to easily collect, validate, report, and submit the results to CMS for payment. The PQRIwizard is powered by the CECity Registry, a CMS-qualified registry for PQRI reporting.

View PQRIwizard for NLA members

Back to Top

CODE RED Survey Now Available

The National Lipid Association (NLA), in partnership with the Association of Black Cardiologists, the Endocrine Society and the American Society for Preventive Cardiology developed a survey to assess your opinions and experiences in managing metabolic syndrome across racial and ethnic subpopulations in the United States.

The survey has been developed as part of CODE RED: Cardiometabolic Disease – COnsortium for the Development of Education to REduce Health Care Disparities, a multi-faceted performance-improvement initiative intended to address the many system-, patient-, and provider-related barriers to the optimal clinical care of patients with cardiometabolic risk factors. Your answers will help establish a rationale for ongoing educational efforts in this program and shape future activities.

Let your voice be heard. Participate today. Thank you.

Take the CODE RED Survey Now

Back to Top

CVD Risk Reduction and Lipid Management: State of the Science in HDL Therapy

The NLA is pleased to announce a NEW nationwide series of CME-certified grand rounds entitled CVD Risk Reduction and Lipid Management: State of the Science in HDL Therapy.  To learn more visit www.rockpointe.com/CVDrisk.

This new series of grand rounds will examine the importance of lipoprotein management for secondary prevention of major adverse cardiac events in post-ACS patients, and feature content developed by Eliot A. Brinton, MD, FAHA, FNLA; Robert S. Rosenson, MD, FACC, FACP, FAHA, FNLA; and Michael Miller, MD, FACC, FAHA.  Participants will learn to recognize residual risk associated with even intense statin therapy to lower LDL, as well as the limitations of current therapies to increase HDL, while building an awareness of the prospects of novel therapies to increase HDL and reduce CVD risk in ACS patients, and to provide primary prevention in high-risk patients. Each grand round program is approved for 1.0 AMA PRA Category 1 Credit^TM.

To bring this CME-certified grand rounds program to your institution, please email rcottman@potomacme.org or call 443-539-4599.

Learn More

Back to Top

FDA Statin Safety Label Changes Coincide with NLA Recommendations

On February 28, 2012, the U.S. Food and Drug Administration (FDA) approved patient safety label changes for statins. These changes, which are based upon the FDA’s comprehensive review of the drug class, are related to monitoring liver enzymes, adverse events and drug interactions.

Read the NLA Response

Back to Top